SCPX (Scorpius Holdings) Debt-to-Revenue : 4.04 (As of Sep. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Scorpius Holdings Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Scorpius Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $3.47 Mil. Scorpius Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $11.43 Mil. Scorpius Holdings's annualized Revenue for the quarter that ended in Sep. 2024 was $3.69 Mil. Scorpius Holdings's annualized Debt-to-Revenue for the quarter that ended in Sep. 2024 was 4.04.

Scorpius Holdings Debt-to-Revenue Historical Data

The historical data trend for Scorpius Holdings's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scorpius Holdings Debt-to-Revenue Chart

Scorpius Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Revenue

Get a 7-Day Free Trial

0.63

N/A

25.13

2.01

Scorpius Holdings Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Debt-to-Revenue	Get a 7-Day Free Trial															4.58	0.72	1.12	5.22	4.04

Competitive Comparison of Scorpius Holdings's Debt-to-Revenue

For the Biotechnology subindustry, Scorpius Holdings's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Scorpius Holdings's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Scorpius Holdings's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Scorpius Holdings's Debt-to-Revenue falls into.

Scorpius Holdings Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Scorpius Holdings's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(1.429	+	12.613)	/	6.995
	=	2.01

Scorpius Holdings's annualized Debt-to-Revenue for the quarter that ended in Sep. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(3.467	+	11.428)	/	3.688
	=	4.04

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Sep. 2024) Revenue data.

Scorpius Holdings Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Scorpius Holdings's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Scorpius Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scorpius Holdings Inc (AMEX:SCPX) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

627 Davis Drive, Suite 400, Morrisville, NC, USA, 27560

Website

https://www.scorpiusbiologics.com

Scorpius Holdings Inc is an integrated contract development and manufacturing organization (CDMO) focused on rapidly advancing biologic and cell therapy programs to the clinic and beyond. It offers a broad array of analytical testing, process development, and manufacturing services to pharmaceutical and biotech companies at its state-of-the-art facilities.

Executives

Prendergast John K A	director	ROBERTS SHERIDAN & KOTEL, 12 EAST 49TH STREET 30TH FL, NEW YORK NY 10017
Jeffrey Alan Wolf	director, officer: Chief Executive Officer	3985 RESEARCH PARK DRIVE, ANN ARBOR MI 48108
Smith Edward B Iii	director	C/O BRIGHTLINE CAPITAL MANAGEMENT, LLC, 1120 AVE OF THE AMERICAS, SUITE 1505, NEW YORK NY 10036
William L. Ostrander	officer: CFO/Corp Secy	801 CAPITOLA DRIVE, SUITE 12, DURHAM NC 27713
John J Monahan	director
Robert James Jakobs	officer: VP Finance/Controller/Secty	PO BOX 14487, DURHAM NC 27709
Jeff Tobin Hutchins	officer: Chief Scientific Officer	15823 S. 4210 RD., CLAREMORE OK 74017
Ann A Rosar	officer: VP of Finance and Controller	C/O 801 CAPITOLA DRIVE, DURHAM NC 27713
Michael Kharitonov	director	100 EUROPA DRIVE, CHAPEL HILL NC 27517
Timothy J Creech	officer: Chief Financial Officer	C/O TRIMERIS, INC., 3518 WESTGATE DR. SUITE 300, DURHAM NC 27707
Stephen J. Dipalma	officer: Interim CFO	C/O SPERO THERAPEUTICS, INC., 675 MASSACHUSETTS AVENUE, 14TH FLOOR, CAMBRIDGE MA 02139
Aristar Heat, Llc	10 percent owner	1120 AVENUE OF THE AMERICAS, SUITE 1514, NEW YORK NY 10036
Aristar Capital Management, Llc	10 percent owner	1120 AVENUE OF THE AMERICAS, SUITE 1514, NEW YORK NY 10036
Aristar Capital Management Gp, Llc	10 percent owner	1120 AVENUE OF THE AMERICAS, SUITE 1514, NEW YORK NY 10036
Taylor Schreiber	officer: Vice President of Research	100 EUROPA DRIVE, CHAPEL HILL NC 27517